Results 211 to 220 of about 96,616 (241)

Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis

Clinical Neuropharmacology, 2022
Abstract Alemtuzumab is a humanized anti-CD52 antibody that is registered for treatment of highly active relapsing-remitting multiple sclerosis. Disease activity after alemtuzumab treatment is infrequent. It may be a result of lack of lymphocyte depletion due to development of neutralizing autoantibodies.
Ivan, Adamec, Mario, Habek
openaire   +2 more sources

Severe, Highly Active, or Aggressive Multiple Sclerosis

Continuum, 2016
Despite the efficacy of current therapies for relapsing forms of multiple sclerosis (MS), there remains a group of patients whose disease fails to respond and warrants a different approach to treatment. This article reviews this form of aggressive MS and proposes a definition and new treatment algorithm.
Mark S, Freedman, Carolina A, Rush
openaire   +2 more sources

Longitudinally Extensive Transverse Myelitis in Highly Active Relapsing-remitting Multiple Sclerosis

Neurology India, 2021
Transverse myelitis in multiple sclerosis is typically a short cord lesion with patchy distribution. Rarely, longitudinally extensive transverse myelitis can be seen in those with highly active disease or frequent relapses. The recognition of this uncommon phenotype in multiple sclerosis is important as the treatment is largely different from other ...
Chen Fei, Ng, Rabani, Remli, Hui Jan, Tan   +2 more
openaire   +2 more sources

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis

Multiple Sclerosis Journal, 2012
Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines recommend alemtuzumab subcutaneous (SC) over IV.
Jai S, Perumal, Farng, Foo, Perry, Cook, Omar, Khan   +3 more
openaire   +2 more sources

Matrix metalloproteinase‐19 is highly expressed in active multiple sclerosis lesions

Neuropathology and Applied Neurobiology, 2006
Matrix metalloproteinases (MMPs) are proteases known for their capacity to degrade extracellular matrix (ECM) components. MMPs have been implicated in several central nervous system (CNS) diseases, including multiple sclerosis (MS). Microarray analysis has demonstrated significant increased mRNA levels of MMP‐19 in chronic MS lesions, suggesting a role
van Horssen, J, Vos, C M P, Admiraal, L, van Haastert, E S, Montagne, L, van der Valk, P, de Vries, H E   +6 more
openaire   +3 more sources

[Effective therapy in highly active pediatric multiple sclerosis].

Ideggyogyaszati szemle, 2021
Multiple sclerosis (MS) is typically a disease of young adults. Childhood MS can be defined in patients under 18 years of age, although some authors set the limit un-der the age of 16 formerly known as "early-onset multiple sclerosis" or "juvenile multiple sclerosis", seen in 3-5% of all MS patients.
Gabriella, Merô, Judit, Móser, Zoltán, Liptai, Péter, Diószeghy, Mónika, Bessenyei, Tünde, Csépány   +5 more
openaire   +1 more source

Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis

European Neurology, 2015
<b><i>Introduction:</i></b> We evaluated the effectiveness of natalizumab in patients with highly active, relapsing-remitting multiple sclerosis (HA-RRMS) to identify baseline predictors associated with freedom from disease activity.
Álvaro, Cobo-Calvo, Laura, Bau, Elisabet, Matas, Lucía, Romero-Pinel, M Alba, Mañé Martínez, Carles, Majós, Sergio, Martínez Yélamos   +6 more
openaire   +2 more sources

173 Outcome in a highly active multiple sclerosis cohort in the UK

Journal of Neurology, Neurosurgery & Psychiatry, 2019
Highly active multiple sclerosis (HAMS) is a clinical phenotype defined by recent disease activity and determines the indication for disease modifying treatments (DMTs). However, prognosis of HAMS is unknown in terms of progression rates.HAMS subjects were recruited to research cohort in 2010. Audits were performed in 2015 and 2019.
Sabrina Kalam, Joe Hill, Ari Baheerathan, Miriam Mattascio, Rehiana Ali, Richard Nicholas, Paolo Muraro   +6 more
openaire   +1 more source

Highly active multiple sclerosis: options for monoclonal antibody therapy

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2019
The clinical course of multiple sclerosis (MS) is characterized by great variability. 'Aggressive' MS, a concept used in the last 10 years, is associated with atypical course of the disease, which is manifested by more frequent exacerbations, the rapid increase in disability and pronounced signs of radiological activity according to MRI.
openaire   +2 more sources

POI03 Using natalizumab in highly active relapsing remitting multiple sclerosis in the UK

Journal of Neurology, Neurosurgery & Psychiatry, 2010
Introduction Natalizumab is licenced in the UK for highly active relapsing remitting multiple sclerosis (RRMS) which is in contrast to the original trials that only studied early RRMS. These original studies demonstrated a reduction in relapse rates of 82% after 1 year compared to the year prior to therapy.
R. Nicholas, C. D'Arcy, P. Muraro, C. McGuigan, O. Malik, P. Giannetti, S. O'Driscoll   +6 more
openaire   +1 more source